FIGURE 3.

GSMs and GSIs differentially compete for PS NTF labeling by RO-57-BpB. A–C, competition assay of PS NTF labeling by RO-57-BpB (1 μm) with other non-acidic GSMs (from Eisai and TorreyPines Therapeutics, each 100 μm) (A), acidic GSMs (sulindac sulfide and GSM-1, each 100 μm) and inverse GSMs (fenofibrate and TO-901317, each 100 μm) (B), and GSIs (L-685,458, DAPT, LY-411,575, and begacestat, each 1 μm) with different mechanisms of action (C). Quantitation of PS NTF binding is shown in the lower panels of A–C. Data are represented as mean ± S.E. (n = 3–6).